ITRM ITERUM THERAPEUTICS PLC Capital Structure Changes 8-K Filing 2025 - Debt Restructuring On May 13, 2025, Iterum Therapeutics plc announced an extension of its milestone payment deferral to Pfizer Inc. related to the FDA approval of ORLYNVAH™, increasing the interest rate to 10% for the new extended period until October 25, 2029.Get access to all SEC 8-K filings of the ITERUM THERAPEUTICS PLC